Could glial activation be a factor in migraine?

Medical Hypotheses

Volumn 72, Issue 3, 2009, Pages 255-257

  Bartley, Jim ^a  

^a The Auckland Regional Pain Service   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EXCITATORY AMINO ACID; IBUDILAST; INTERLEUKIN 10; MINOCYCLINE; NALOXONE; NALTREXONE; NITRIC OXIDE; PENTOXIFYLLINE; PROPENTOFYLLINE; VITAMIN D;

ARTICLE; ASTROCYTE; BRAIN STEM; CELL ACTIVATION; CYTOKINE PRODUCTION; DIENCEPHALON; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLIA CELL; HUMAN; MICROGLIA; MIGRAINE; NERVE CELL; NERVE CONDUCTION; NERVE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SENSORY DYSFUNCTION; SENSORY NERVE;

BRAIN; CYTOKINES; FIBROBLAST GROWTH FACTOR 9; HUMANS; INFLAMMATION MEDIATORS; MIGRAINE DISORDERS; MODELS, NEUROLOGICAL; NEUROGLIA;

EID: 59449097710     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.09.048     Document Type: Article

References (25)

1. Bartley J. Healing headaches (2008), Auckland, Random House
2. Dodick D., and Silberstein S. Central sensitization theory of migraine: clinical implications. Headache 46 Suppl. 4 (2006) S182-S191
3. Weiller C., May A., Limmroth V., et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 7 (1995) 658-660
4. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Eng J Med 346 (2002) 257-270
5. Doods A., Arndt K., Rudolf K., and Just S. CGRP antagonists: unraveling the role of CGRP in migraine. Trends Pharmacol Sci 28 (2007) 580-587
6. Watkins L.R., Milligan E.D., and Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 24 (2001) 450-455
7. Watkins L.R., Milligan E.D., and Maier S.F. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 521 (2003) 1-21
8. Hutchinson M.R., Bland S.T., Johnson K.W., et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorld J 7 (2007) 98-111
9. Mett A., and Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 21 (2008) 331-337
10. Tang A.H., and Collins R.T. Chronic naloxone results in prolonged increase in opiate binding sites in the brain. Eur J Pharmacol 51 (1978) 185-186
11. Egger J., Carter C.M., Wilson J., Turner M.W., and Soothill J.F. Is migraine food allergy? A double blind controlled trial of oligoantigenic diet. Lancet 2 (1983) 865-869
12. Pradalier A. Immunological aspects of migraine. In: Olesen J., Tfelt P., and Welch K.M.A. (Eds). The headaches (2000), Williams and Wilkins, Lipincott, Philadelphia
13. Hadjivassilou M., Gibson A., Davies-Jones G.A.B., et al. Does cryptic gluten sensitivity play a part in neurological illness. Lancet 347 (1996) 369-371
14. Hadjivassilou M., Grunewald R.A., Lawden M., et al. Headache and CNS white abnormalities associated with gluten sensitivity. Neurology 56 (2001) 385-388
15. Teschemacher H. Opioid receptor ligands derived from food proteins. Curr Pharm Des 9 (2003) 1331-1344
16. Mika J., Osikowicz M., Makuch W., and Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 560 (2007) 142-149
17. Sweitzer S.M., Schubert P., and DeLeo J.A. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 297 (2001) 1210-1217
18. Ledeboer A., Hutchinson M.R., Watkins L.R., and Johnson K.W. Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Exp Opin Investig Drugs 16 (2007) 935-950
19. Milligan E.D., Sloane E.M., Langer S.J., et al. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 126 (2006) 294-308
20. Nicolodi M., and Sicuteri F. Chronic naloxone administration, a potential treatment for migraine enhances morphine-induced miosis. Headache 32 (1992) 348-452
21. Centonze V., Brucoli C., Maciniagrossa G., et al. Non-familial hemiplegic migraine responsive to naloxone. Cephalalgia 3 (1983) 125-127
22. Sicuteri F., Boccuni M., Fanciulacci M., and Gatto G. Naloxone effectiveness on spontaneous and induced perceptive disorders in migraine. Cephalalgia 23 (1983) 179-183
23. Shimomura T., Kowa H., and Takahashi K. Analgesic-induced headaches: successful treatment with Ibudilast. Headache 31 (1991) 483
24. Thys-Jacobs S. Alleviation of migraines with therapeutic vitamin D and calcium. Headache 34 (1994) 590-592
25. Garcion E., Sindji L., Leblondel G., Brachet P., and Darcy F. 1, 25-Dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem 73 (1999) 859-866